ET occurring in NPM1-mutated AML during molecular complete remission: A further potential evolution of a complex disease

Br J Haematol. 2025 Nov;207(5):2153-2157. doi: 10.1111/bjh.70076. Epub 2025 Aug 13.

Abstract

Nucleophosmin 1 (NPM1)mut acute myeloid leukaemia (AML) patients may experience different disease evolutions after achieving complete remission. Essential thrombocythaemia (ET) may arise in ≈3% of NPM1mutAML patients achieving molecular remission after treatment. The presence of JAK2V617F mutation within the persisting clonal haematopoietic background of NPM1mutAML favours the development of ET among other myeloid malignancies during NPM1wtAML remission.

Keywords: leukaemia markers; molecular diagnostics; myeloid leukaemia.

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Female
  • Humans
  • Janus Kinase 2 / genetics
  • Leukemia, Myeloid, Acute* / complications
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / therapy
  • Male
  • Middle Aged
  • Mutation*
  • Nuclear Proteins* / genetics
  • Nucleophosmin
  • Remission Induction
  • Thrombocythemia, Essential* / etiology
  • Thrombocythemia, Essential* / genetics

Substances

  • JAK2 protein, human
  • Janus Kinase 2
  • NPM1 protein, human
  • Nuclear Proteins
  • Nucleophosmin